Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board PR Newswire - Tue Jul 18, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 8.13 (-3.56%)
KA : 0.6068 (+8.09%)
APRE : 3.88 (+3.19%)
XFOR : 0.5489 (-2.76%)
Biotech Bid Up Following First Patient Dosage Yolowire - Wed Jan 11, 2023

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead...

APRE : 3.88 (+3.19%)
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results Globe Newswire - Mon May 16, 2022

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 3.88 (+3.19%)
First Week of May 20th Options Trading For Aprea Therapeutics (APRE) Dividend Channel - Tue Mar 22, 2022

Investors in Aprea Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APRE options chain...

APRE : 3.88 (+3.19%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations Globe Newswire - Tue Mar 15, 2022

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 3.88 (+3.19%)
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting Globe Newswire - Mon Dec 13, 2021

60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. ...

APRE : 3.88 (+3.19%)
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations Globe Newswire - Mon Nov 8, 2021

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 3.88 (+3.19%)
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting Globe Newswire - Thu Nov 4, 2021

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 3.88 (+3.19%)
Stocks-Money-Rates - Stock Market Ticker on Laptop
Pre-Market Brief: U.S. Stocks to Open Higher on Strong U.S. Housing Data Barchart - Tue Sep 21, 2021

Morning Markets Dec S&P 500 futures this morning are up by +0.62%. U.S. stock index futures are climbing today as the markets partially recover from Monday’s plunge on some dip-buying. Also, a rally...

JD : 26.76 (-0.41%)
PDD : 136.19 (-0.84%)
BABA : 74.52 (-1.39%)
NTES : 91.96 (-4.13%)
BIDU : 88.97 (-1.21%)
COP : 112.55 (-1.93%)
SRAD : 10.99 (-2.14%)
OXY : 61.79 (-0.85%)
LEN : 142.63 (-0.11%)
APRE : 3.88 (+3.19%)
OEG : 0.6431 (+8.08%)
KAR : 16.75 (-0.42%)
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021 Globe NewsWire - Mon Sep 20, 2021

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...

APRE : 3.88 (+3.19%)

Barchart Exclusives

1 ETF Set to Benefit from the Weak Japanese Yen Barchart - 21 minutes ago
The Japanese stock market, driven by powerful exporters like Toyota, could benefit from persistent weakness in the yen. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot